Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris' President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ACRS
The Conversation (0)
Alvopetro Announces Q3 2026 Financial Results and an Operational Update Including 183-G2 Well Results

Alvopetro Announces Q3 2026 Financial Results and an Operational Update Including 183-G2 Well Results

Alvopetro Energy Ltd. (TSXV: ALV,OTC:ALVOF) (OTCQX: ALVOF) ("Alvopetro" or the "Company") announces an operational update including initial results from our 183-G2 well, our financial results for the three and nine months ended September 30, 2026, and updated details for our Q3 2026 earnings... Keep Reading...
Davidson River Drilling Doubles Thunderbird Corridor Width, Intersects Dravite-Clay Alteration Across All Tested Trends

Davidson River Drilling Doubles Thunderbird Corridor Width, Intersects Dravite-Clay Alteration Across All Tested Trends

Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to provide additional geological highlights and interpretations from its summer 2026 drill program at its flagship Davidson River Uranium Project ("Davidson River", or the "Project")... Keep Reading...
FORTUNE BAY AND MANHATTAN URANIUM INTERSECT ANOMALOUS RADIOACTIVITY IN SIX DRILL HOLES AT MURMAC AND STRIKE

FORTUNE BAY AND MANHATTAN URANIUM INTERSECT ANOMALOUS RADIOACTIVITY IN SIX DRILL HOLES AT MURMAC AND STRIKE

Multiple near-surface zones and favourable geological observations help define follow-up uranium exploration targets in the Athabasca Basin Fortune Bay Corp. (TSXV: FOR,OTC:FTBYF) (FWB: 5QN) (OTCQB: FTBYF) ("Fortune Bay" or the "Company") is pleased to announce completion of the 2026 summer... Keep Reading...
Standard Uranium Upsizes LIFE Offering

Standard Uranium Upsizes LIFE Offering

Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has increased the size of its previously announced non-brokered private placement (the "Offering") being conducted in reliance upon the listed issuer financing... Keep Reading...
Standard Uranium Confirms Strong Radioactivity up to 48,000 cps at Surface and Discovers New Showings at the Corvo Uranium Project

Standard Uranium Confirms Strong Radioactivity up to 48,000 cps at Surface and Discovers New Showings at the Corvo Uranium Project

Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce preliminary results from its 2026 ground exploration program (the "Program") at the Corvo Uranium Project ("Corvo", or the "Project"), currently under a three-year earn-in... Keep Reading...

Interactive Chart

Latest Press Releases

Related News